CURLF Curaleaf Holdings, Inc.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1756770 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-0.9%
TTM net income YoY23.4%
TTM EPS YoY17.9%
Revenue 3-yr CAGR3.7%
Net income 3-yr CAGR—
Margins
Gross margin48.0%
Operating margin1.9%
Net margin-16.1%
FCF margin5.3%
EBITDA margin19.2%
Returns
ROE-22.5%
ROA-7.1%
ROIC (approx.)1.4%
Asset turnover0.44x
Leverage & solvency
Liabilities / assets66.3%
Debt / equity0.66x
Current ratio1.12x
Interest coverage0.47x
Cash quality & payout
Operating cash flow / net income-0.76x
Accruals ratio-12.5%
Payout ratio—
Capex / revenue6.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.27B | $1.33B | $1.35B | $1.28B | $1.20B |
| Cost of revenue | $637.11M | $693.52M | $732.18M | $649.00M | $626.16M |
| Gross profit | $631.02M | $640.78M | $614.45M | $626.42M | $569.83M |
| R&D expense | $805,000 | $1.42M | — | — | — |
| SG&A expense | $428.44M | $418.53M | $414.77M | $419.88M | $386.64M |
| Operating income | $25.45M | $24.74M | $42.88M | $64.99M | $58.57M |
| Interest expense | $53.52M | $53.19M | $53.71M | — | $53.55M |
| Pretax income | -$78.21M | -$113.36M | -$124.37M | -$86.49M | -$62.20M |
| Income tax | $123.69M | $98.25M | $114.59M | $178.82M | $152.44M |
| Net income | -$231.07M | -$215.42M | -$281.20M | -$370.10M | -$205.94M |
| EBITDA | $222.06M | $256.20M | $238.76M | $220.97M | $179.12M |
| EPS (basic) | -0.35 | -0.32 | -0.39 | -0.52 | -0.29 |
| EPS (diluted) | -0.35 | -0.32 | -0.39 | -0.52 | -0.29 |
| Weighted avg. shares (diluted) | 762.09M | 740.83M | 724.12M | 711.16M | 698.76M |
| Balance sheet | |||||
| Cash & equivalents | $89.21M | $107.22M | $91.82M | $163.18M | $299.33M |
| Receivables | $73.86M | $63.99M | $60.00M | $45.18M | $60.43M |
| Inventory | $225.02M | $216.94M | $215.91M | $234.78M | $248.15M |
| Current assets | $448.62M | $434.37M | $418.60M | $652.42M | $726.62M |
| PP&E, net | $520.39M | $542.60M | $571.63M | $595.85M | $525.83M |
| Goodwill | $635.12M | $628.88M | $626.63M | $625.13M | $571.65M |
| Intangibles | $1.01B | $1.09B | $1.17B | $1.21B | $1.04B |
| Total assets | $2.85B | $2.95B | $3.10B | $3.41B | $3.11B |
| Current liabilities | $294.31M | $387.93M | $494.03M | $496.87M | $316.24M |
| Short-term debt | $35.73M | $101.72M | $39.48M | $51.88M | $1.97M |
| Long-term debt | $512.92M | $466.90M | $548.29M | $570.79M | $457.92M |
| Total debt | $548.65M | $568.62M | $587.77M | $622.67M | $459.88M |
| Total liabilities | $2.01B | $1.96B | $1.93B | $2.01B | $1.44B |
| Shareholders' equity | $756.35M | $861.21M | $1.05B | $1.28B | $1.55B |
| Net debt | $459.44M | $461.39M | $495.95M | $459.49M | $160.55M |
| Shares outstanding | 257.49M | 750.06M | 733.73M | 717.49M | 708.34M |
| Cash flow statement | |||||
| Operating cash flow | $137.71M | $163.62M | $75.26M | $46.40M | -$58.28M |
| Capital expenditure | $63.44M | $92.44M | $65.45M | $134.64M | $171.96M |
| Free cash flow | $74.27M | $71.19M | $9.81M | -$88.24M | -$230.24M |
| Investing cash flow | -$70.34M | -$93.83M | -$78.69M | -$219.88M | -$163.97M |
| Financing cash flow | -$73.49M | -$54.24M | -$67.02M | $41.79M | $449.12M |
| Depreciation & amortization | $196.61M | $231.46M | $195.88M | $155.98M | $120.54M |
| Stock-based compensation | $35.74M | $25.70M | $20.01M | $28.02M | $39.48M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.